Nonviral vector gene modification of stem cells for myocardial repair

Husnain K. Haider, Ibrahim Elmadbouh, Michel Jean-Baptiste, Muhammad Ashraf

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

Therapeutic angiogenesis and myogenesis restore perfusion of ischemic myocardium and improve left ventricular contractility. These therapeutic modalities must be considered as complementary rather than competing to exploit their advantages for optimal beneficial effects. The resistant nature of cardiomyocytes to gene transfection can be overcome by ex vivo delivery of therapeutic genes to the heart using genetically modified stem cells. This review article gives an overview of different vectors and delivery systems in general used for therapeutic gene delivery to the heart and provides a critical appreciation of the ex vivo gene delivery approach using genetically modified stem cells to achieve angiomyogenesis for the treatment of infarcted heart.

Original languageEnglish (US)
Pages (from-to)79-86
Number of pages8
JournalMolecular Medicine
Volume14
Issue number1-2
DOIs
StatePublished - Jan 1 2008

Fingerprint

Stem Cells
Genes
Muscle Development
Therapeutics
Cardiac Myocytes
Transfection
Myocardium
Perfusion

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Nonviral vector gene modification of stem cells for myocardial repair. / Haider, Husnain K.; Elmadbouh, Ibrahim; Jean-Baptiste, Michel; Ashraf, Muhammad.

In: Molecular Medicine, Vol. 14, No. 1-2, 01.01.2008, p. 79-86.

Research output: Contribution to journalReview article

Haider, Husnain K. ; Elmadbouh, Ibrahim ; Jean-Baptiste, Michel ; Ashraf, Muhammad. / Nonviral vector gene modification of stem cells for myocardial repair. In: Molecular Medicine. 2008 ; Vol. 14, No. 1-2. pp. 79-86.
@article{dff614bfd7e143cab23a0e83be97cf5f,
title = "Nonviral vector gene modification of stem cells for myocardial repair",
abstract = "Therapeutic angiogenesis and myogenesis restore perfusion of ischemic myocardium and improve left ventricular contractility. These therapeutic modalities must be considered as complementary rather than competing to exploit their advantages for optimal beneficial effects. The resistant nature of cardiomyocytes to gene transfection can be overcome by ex vivo delivery of therapeutic genes to the heart using genetically modified stem cells. This review article gives an overview of different vectors and delivery systems in general used for therapeutic gene delivery to the heart and provides a critical appreciation of the ex vivo gene delivery approach using genetically modified stem cells to achieve angiomyogenesis for the treatment of infarcted heart.",
author = "Haider, {Husnain K.} and Ibrahim Elmadbouh and Michel Jean-Baptiste and Muhammad Ashraf",
year = "2008",
month = "1",
day = "1",
doi = "10.2119/2007-00092.Haider",
language = "English (US)",
volume = "14",
pages = "79--86",
journal = "Molecular Medicine",
issn = "1076-1551",
publisher = "Feinstein Institute for Medical Research",
number = "1-2",

}

TY - JOUR

T1 - Nonviral vector gene modification of stem cells for myocardial repair

AU - Haider, Husnain K.

AU - Elmadbouh, Ibrahim

AU - Jean-Baptiste, Michel

AU - Ashraf, Muhammad

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Therapeutic angiogenesis and myogenesis restore perfusion of ischemic myocardium and improve left ventricular contractility. These therapeutic modalities must be considered as complementary rather than competing to exploit their advantages for optimal beneficial effects. The resistant nature of cardiomyocytes to gene transfection can be overcome by ex vivo delivery of therapeutic genes to the heart using genetically modified stem cells. This review article gives an overview of different vectors and delivery systems in general used for therapeutic gene delivery to the heart and provides a critical appreciation of the ex vivo gene delivery approach using genetically modified stem cells to achieve angiomyogenesis for the treatment of infarcted heart.

AB - Therapeutic angiogenesis and myogenesis restore perfusion of ischemic myocardium and improve left ventricular contractility. These therapeutic modalities must be considered as complementary rather than competing to exploit their advantages for optimal beneficial effects. The resistant nature of cardiomyocytes to gene transfection can be overcome by ex vivo delivery of therapeutic genes to the heart using genetically modified stem cells. This review article gives an overview of different vectors and delivery systems in general used for therapeutic gene delivery to the heart and provides a critical appreciation of the ex vivo gene delivery approach using genetically modified stem cells to achieve angiomyogenesis for the treatment of infarcted heart.

UR - http://www.scopus.com/inward/record.url?scp=40349084307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40349084307&partnerID=8YFLogxK

U2 - 10.2119/2007-00092.Haider

DO - 10.2119/2007-00092.Haider

M3 - Review article

VL - 14

SP - 79

EP - 86

JO - Molecular Medicine

JF - Molecular Medicine

SN - 1076-1551

IS - 1-2

ER -